In a Phase 1 study, nine people with advanced kidney cancer became cancer free after receiving personalized vaccines.

The fusion of mRNA technology with AI has laid the foundation for ushering in a new era of cancer care. However, conducting ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

personalized cancer vaccine, researchers reported Feb. 5. The small, phase 1 trial was carried out by the Dana-Farber Cancer Institute, with the results published in Nature on Wednesday.

Harnessing AI to Revolutionize Vaccine and Therapy Development ATLANTA, GA - (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX ...

“This is our first paper at the intersection of AI ... vaccine research. By providing a reliable method to predict immunodominant epitopes which are those most-easily recognized by the immune system, ...

An exciting collaboration between the Ragon Institute and the Jameel Clinic at MIT has achieved a significant milestone in leveraging artificial intelligence (AI) to aid the development of T cell ...

A collaboration between the Ragon Institute and the Jameel Clinic at MIT has achieved a significant milestone in leveraging ...

An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the vaccine candidate appeared to be safe and produced a clear immune ...

Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell carcinoma (ccRCC), the most common type of kidney cancer among adults.

The proposed guidance aims to provide a framework for the approval of personalised mRNA-based cancer vaccines.